BioArctic Neuroscience and Eisai Enter Into Licensing Agreement

The antibody targets the neurotoxin believed to cause Alzheimer’s disease.

Stockholm, Sweden, and Tokyo, Japan, December 3rd 2007. The Swedish biopharmaceutical company BioArctic Neuroscience AB and the Japanese pharmaceutical company Eisai Co. Ltd., today announced that they have signed an exclusive licence agreement for BAN2401, a novel humanized monoclonal antibody, which is being developed as a next-generation treatment for Alzheimer´s disease.